RT MicroDx develops saliva-based molecular testing solutions that deliver PCR-quality results at home within minutes, addressing the need for accurate diagnostics without the discomfort and costs associated with traditional lab tests. By providing affordable and self-administered tests, the company empowers individuals to manage their health conveniently and effectively.
Funding
Funding not disclosed
Founders
Product
Problem
Millions of patients seek medical attention for bacterial infection symptoms annually, with a significant percentage testing negative. Traditional testing methods require time off, incur uncovered expenses, and can be invasive, leading to delayed diagnosis and potential exposure to hospital-acquired infections.
Solution
RT MicroDx offers a saliva-based, at-home molecular testing platform that delivers PCR-quality results in minutes. The platform enables individuals to conveniently and affordably test for infections without the need for a clinic visit. By utilizing an isothermal amplification method (LAMP), the test accurately detects infections in saliva, mitigating the impact of oral variations. The results are displayed on a simple assay strip, making it easy for consumers to interpret. This approach aims to decentralize diagnostics, providing equitable access to testing and facilitating timely telehealth integration for diagnosis and treatment.
Target Audience
The primary target audience includes individuals seeking convenient and affordable diagnostic testing options, parents needing quick results for their children's illnesses, and healthcare providers looking to integrate accessible testing solutions into telehealth platforms.
Features
- Saliva-based sample collection, eliminating the need for invasive nasal or throat swabs
- Isothermal amplification (LAMP) technology for rapid and accurate molecular detection
- Assay strip result display for easy interpretation
- High sensitivity (99%) and specificity (97%) comparable to lab-based PCR tests
- Results available in approximately 35 minutes
- Potential for integration with telehealth platforms for immediate diagnosis and treatment
- Platform adaptable for detecting various infections, including strep throat and mononucleosis